Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2021 Nov 17;172(1):49–52. doi: 10.1007/s10517-021-05329-7

Development of a Purified Viral Preparation for Studies of COVID-19 (SARS-CoV-2) Biology

A A Chepurnov 1,, E I Kazachinskaya 1, E A Kazachkova 1, K A Sharshov 1, Yu V Kononova 1, A A Shelemba 1, A Yu Alekseev 1, M A Gulyeva 1, M I Voevoda 1, A M Shestopalov 1
PMCID: PMC8596366  PMID: 34787781

Abstract

Different methods for producing bulk quantities of concentrated and purified SARS-CoV-2 for the use as antigens and for the research into COVID-19 biology were tested.

Key Words: SARS-CoV-2, 2002 year SARS-CoV, electrophoresis, purified virus preparations

Footnotes

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 172, No. 7, pp. 60-64, July, 2021

References

  • 1.Ustinova EN, Shestopalov AM, Bakulina LF, Chepurnov AA. Titration of Ebola and Marburg viruses by plaque formation under semi liquid agar cover. Vopr. Virusol. 2003;48(1):43-44. Rusian. [PubMed]
  • 2.Chepurnov AA, Dadaeva AA, Malkova EM, Sandakhchiev LS, Kolesnikov RSI. Symptoms of infection caused by SARS coronavirus in laboratory mice and guinea pigs. Dokl. Biol. Sci. 2004;397(1-6):310–313. doi: 10.1023/B:DOBS.0000039701.92375.b6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Chepurnov AA, Merzlikin NV, Ryabchikova EI, Chepurnova TS, Volchkov VE, Istomina NN, Kuzmin VA, Vorobeva MS. Isolation of purified Ebola virus. Vopr. Virusol. 1994;39(6):254–257. [PubMed] [Google Scholar]
  • 4.Chepurnov AA, Sharshov KA, Kazachinskaya EI, Kononova YV, Kazachkova EA, Khripko OP, Yurchenko KS, Alekseev AY, Voevoda MI, Shestopalov AM. Antigenic properties of SARS-CoV-2/HUMAN/RUS/NSK-FRCFTM-1/2020 coronavirus isolate from a patient in Novosibirsk. Zh. Infectol. 2020;12(3):42–50. doi: 10.22625/2072-6732-2020-12-3-42-50. [DOI] [Google Scholar]
  • 5.Bielinska AU, Chepurnov AA, Landers JJ, Janczak KW, Chepurnova TS, Luker GD, Baker JR. A novel, killedvirus nasal vaccinia virus vaccine. Clin. Vaccine Immunol. 2008;15(2):348–358. doi: 10.1128/CVI.00440-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Chepurnov AA, Bakulina LF, Dadaeva AA, Ustinova EN, Chepurnova TS, Baker JR., Jr Inactivation of Ebola virus with a surfactant nanoemulsion. Acta Trop. 2003;87(3):315–320. doi: 10.1016/s0001-706x(03)00120-7. [DOI] [PubMed] [Google Scholar]
  • 7.Chepurnov AA, Tuzova MN, Ternovoy VA, Chernukhin IV. Suppressive effect of Ebola virus on T cell proliferation in vitro is provided by a 125-kDa GP viral protein. Immunol. Lett. 1999;68(2-3):257–261. doi: 10.1016/s0165-2478(99)00058-9. [DOI] [PubMed] [Google Scholar]
  • 8.Dent S, Neuman BW. Purification of coronavirus virions for Cryo-EM and proteomic analysis. Methods Mol. Biol. 2015;1282:99–108. doi: 10.1007/978-1-4939-2438-7_10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369:77–81. doi: 10.1126/science.abc1932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hamouda T, Chepurnov A, Mank N, Knowlton J, Chepurnova T, Myc A, Sutcliffe J, Baker JR. Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum. Vaccin. 2010;6(7):585–594. doi: 10.4161/hv.6.7.11818. [DOI] [PubMed] [Google Scholar]
  • 11.Neuman BW, Adair BD, Yeager M, Buchmeier MJ. Purification and electron cryomicroscopy of coronavirus particles. Methods Mol. Biol. 2008;454:129–136. doi: 10.1007/978-1-59745-181-9_12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Salk J, Salk D. Control of influenza and poliomyelitis with killed virus vaccines. Science. 1977;195:834–847. doi: 10.1126/science.320661. [DOI] [PubMed] [Google Scholar]
  • 13.Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C, Lou Z, Xu M, Qin C, Wu G, Gao GF, Tan W, Yang X. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020;182(3):713–721.e9. doi: 10.1016/j.cell.2020.06.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.WHO Coronavirus (COVID-19) Dashboard. World Health Organization. [URL: https://covid19.who.int/].
  • 15.Yan Y, Diao B, Liu Y, Zhang W, Wang G, Chen X. Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Protein in the Ocular Tissues of a Patient Previously Infected With Coronavirus Disease 2019. JAMA Ophthalmol. 2020;138(11):1201–1204. doi: 10.1001/jamaophthalmol.2020.3962. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Bulletin of Experimental Biology and Medicine are provided here courtesy of Nature Publishing Group

RESOURCES